Why Is BIOCRYST PHARMACEUTI (BCRX) Stock Moving Today?

Why BCRX stock is down today

BioCryst Pharmaceuticals shares fell 7.55% in pre-market trading on Thursday to $8.14. The decline followed a downgrade from RBC Capital, which cut the stock to Sector Perform from Outperform. The move comes amid broader market weakness and mixed analyst coverage, with some maintaining bullish positions while others have reduced their outlook.

What Happened

RBC Capital’s downgrade was the most immediate catalyst for the stock’s decline. The firm adjusted its rating to Sector Perform from Outperform, signaling a shift in its relative confidence in BioCryst’s performance compared to its peers. This downgrade occurred alongside a broader sell-off in the market, with several large stocks falling in pre-market trading. Meanwhile, BioCryst announced a partnership with CareMed to expand the distribution of Orladeyo, its treatment for hereditary angioedema. However, the news failed to offset the negative sentiment from the downgrade.

The company remains unprofitable with a trailing twelve-month net margin of -40.9% and an earnings per share of -1.68. Despite a 68.7% year-to-date revenue increase, the stock has struggled to maintain momentum. Recent coverage has highlighted BioCryst as part of a group of healthcare stocks with strong revenue growth but mixed valuation grades.

What The Data Shows

The stock opened at $8.66, reflecting a -1.6% gap from the prior close. It quickly declined to an intraday low of $8.05 before stabilizing slightly. The session volume of 1.0 million shares is 0.2 times the 3-month daily average, indicating limited liquidity. The stock has now printed two fresh 52-week lows on September 10. Sentiment has deteriorated in the last seven days, with an average score of 53 out of 100, down from 60 over the past 30 days.

What To Watch

BioCryst has no scheduled earnings report in the near term. Investors should monitor the breadth of analyst coverage and any further updates on the company’s partnership with CareMed.